In this episode, we chatted with Molly Gibson, Co-Founder of Generate Biomedicines, a biotech that uses AI/ML to generate novel protein medicines and recently closed a $370M Series B financing. We discussed the key trends in computationally-powered drug discovery and bioplatforms, what it takes to commercialize early-stage biotechnology, and much more. 

Founded in 2018 under the Flagship Pioneering ecosystem, Generate Biomedicines leverages machine intelligence to computationally generate de-novo (i.e., never-before-seen) protein therapeutics.

Molly Gibson, Co-Founder of Generate Bio, on Innovating at the Intersection of AI/ML and Biotech

In this episode, we sat down with Dr. Ali Behbahani, General Partner at New Enterprise Associates. Dr. Behbahani has been with NEA since 2007, spearheading over 40 biotech and medtech investments such as CRISPR Therapeutics, Adaptimmune, and Nevro. We discussed his views on breaking into VC, his approach to assessing early-stage life science innovations, the current trends in the biotech investing landscape, and much more.

NEA is a global VC firm with $25B in AUM and over 300 active investments across both technology and healthcare sectors. Founded in 1977, NEA has made transformational investments such as Robinhood, Salesforce, Bright Health, and CRISPR Therapeutics. NEA has offices in Menlo Park, San Francisco, New York, and the Washington, D.C. metro area, and is widely considered one of the largest leading VCs in the world.

Dr. Ali Behbahani, Partner at NEA, on evaluating and investing in cutting-edge life sciences

In this episode, we sat down with Dr. Osvaldo (Lalo) Flores, CEO at Century Therapeutics. We discuss Lalo's early career in R&D, the founding story (and eventual acquisition) of Novira Therapeutics, and his outlook on next-generation cell therapies with Century.

Century Therapeutics is a biotechnology company developing transformative allogeneic cell therapies to create products for both hematological and solid tumor malignancies. In January 2022, Century entered into a strategic collaboration with Bristol Myers Squibb (BMS) to develop induced pluripotent stem cell (IPSC)-derived allogeneic cell therapies. Century is based in Philadelphia, PA.

Lalo Flores, CEO at Century Therapeutics, on Developing Next-Generation Cell Therapies

LifeSci Beat is a Wharton MBA student-run podcast dedicated to exploring the business of innovation in the life sciences. We are focused on chronicling the latest discoveries in life sciences (biotech, medtech, diagnostics, and more) and uncovering the business challenges faced by leaders in bringing cutting edge technology to market.

Lalo Flores, CEO at Century Therapeutics, on Developing Next-Generation Cell Therapies

LifeSci Beat

Related tracks